

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

## Spevigo (spesolimab)

PHYSICIAN INFORMATION			PATIENT INFORMATION					
* Physician's Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this					
Specialty:	* DEA, NPI or	TIN:	form are completed.*					
Office Contact Person:			* Patient Name:					
Office Phone:			* Cigna ID:	a ID: * Date of Birth:		Birth:		
Office Fax:			* Patient Street Address:					
Office Street Address:			City	State Zip		Zip		
City	State	Zip	Patient Phone:	1				
Urgency: ☐ Standard	☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication requested:								
☐ Spevigo vial for intravenous ☐ Spevigo subcutaneous ☐ ICD10:								
Dose and Quantity: Frequency of administration:								
How much does the patient weigh? ☐ Less than 40 kilograms (kg) ☐ 40 kilograms (kg) or more								
Where will this medication be obtained?  Accredo Specialty Pharmacy**  Hospital Outpatient Retail pharmacy Other (please specify):			☐ Home Health / Home Infusion vendor ☐ Physician's office stock (billing on a medical claim form) **Cigna's nationally preferred specialty pharmacy					
**Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822   NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557								
Facility and/or doctor dispensing and administering medication:								
Facility Name: State: Address (City, State, Zip Code):		Tax ID#:						
Where will this drug be administered? ☐ Patient's Home ☐ Hospital Outpatient			☐ Physician's Office ☐ Other (please specify):					
<b>NOTE:</b> Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.								
Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager?  Yes No (provide medical necessity rationale):								
Is the requested medication for a chronic or long-term condition for which the prescription medicathe patient?					be necess	sary for the life of ☐ Yes ☐ No		

Clinical Information:  **This drug REQUIRES supportive documentation for ALL answers, including chart notes, lab/test results be submitted with this request.**  Will the requested medication be used in combination with another biologic prescribed for treatment of generalized pustular psoriasis? Please Note: Patients with concomitant plaque psoriasis and generalized pustular psoriasis may be receiving a biologic for treatment of plaque psoriasis.  Does the patient weight greater than or equal to 40 kilograms (kg)?  Is the requested medication being prescribed by or in consultation with a dermatologist?  Is the patient experiencing a flare of moderate-to-severe intensity?  Is the patient currently receiving Spevigo subcutaneous?  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of greater than or equal to 3 points? Please Note: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score anges from 0 (clear skin) to 4 (severe disease).  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points? Please Note: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points? Please Note: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Does the patient have enew or worsening pustules?  Does the patient have enew or worsening pustules?  Has patient have erythema and pustules which affects greater than or equal to 5% of body surface area?  Yes No  Has the patient already received two doses of Spevigo intravenous for treatment of the current flare?  Has the patient already received two doses of Spevigo intravenous for a previous flare?  Has the patient already received two doses of Spevigo intravenous for a previous flare?  Has the patient already received two doses of Spevigo intravenous for a previous flare?	What is the indication or diagnosis?  Generalized Pustular Psoriasis Flare Plaque Psoriasis other (please specify):	
Will the requested medication be used in combination with another biologic prescribed for treatment of generalized pustular psoriasis? Please Note: Patients with concomitant plaque psoriasis and generalized pustular psoriasis may be receiving a biologic for treatment of plaque psoriasis.  Does the patient weight greater than or equal to 40 kilograms (kg)?  Is the requested medication being prescribed by or in consultation with a dermatologist?  Is the patient experiencing a flare of moderate-to-severe intensity?  Is the patient currently receiving Spevigo subcutaneous?  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of greater than or equal to 3 points? Please Note: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score ranges from 0 [clear skin] to 4 [severe disease].  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Pyes No  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Pyes No  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Pyes No  Has patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Pyes No  Has the patient already received Spevigo intravenous?  Pyes No  Has the patient already recei	Clinical Information:	
Please Note: Patients with concomitant plaque psoriasis and generalized pustular psoriasis may be receiving a biologic for treatment of plaque psoriasis.  Does the patient weight greater than or equal to 40 kilograms (kg)?  Is the requested medication being prescribed by or in consultation with a dermatologist?  Yes No  Is the patient experiencing a flare of moderate-to-severe intensity?  Yes No  Is the patient currently receiving Spevigo subcutaneous?  Does the patient thave a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of greater than or equal to 3 points? Please Note: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score ranges from 0 [clear skin] to 4 [severe disease].  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?  Does the patient have new or worsening pustules?  Does the patient have envy thema and pustules which affects greater than or equal to 5% of body surface area?  Yes No  Has patient had increase in GPPGA total score > or = to 2 points  Has the patient already received Spevigo intravenous?  Yes No  Has the patient already received two doses of Spevigo intravenous for treatment of the current flare?  Yes No  Has the patient already received two doses of Spevigo intravenous for a previous flare?  Yes No  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Yes No  Have at least 12 weeks have elapsed since the last dose of Spevigo?		results be
Is the requested medication being prescribed by or in consultation with a dermatologist?    Yes   No	Please Note: Patients with concomitant plaque psoriasis and generalized pustular psoriasis may be receiving a biolog	gic for treatment of
Is the patient experiencing a flare of moderate-to-severe intensity?   Yes   No   Is the patient currently receiving Spevigo subcutaneous?   Yes   No   Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of greater than or equal to 3 points? Please Note: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score ranges from 0 [clear skin] to 4 [severe disease].   No   Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of greater than or equal to 2 points?   Yes   No   Does the patient have new or worsening pustules?   Yes   No   Does the patient have erythema and pustules which affects greater than or equal to 5% of body surface area?   Yes   No   Has patient had increase in GPPGA total score > or = to 2 points   Yes   No   Has the patient already received Spevigo intravenous?   Yes   No   Has the patient already received two doses of Spevigo intravenous for treatment of the current flare?   Yes   No   Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No   Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No   Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No	Does the patient weight greater than or equal to 40 kilograms (kg)?	☐ Yes ☐ No
Is the patient currently receiving Spevigo subcutaneous?	Is the requested medication being prescribed by or in consultation with a dermatologist?	☐ Yes ☐ No
Does the patient have a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score of greater than or equal to 3 points? Please Note: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score ranges from 0 [clear skin] to 4 [severe disease].	Is the patient experiencing a flare of moderate-to-severe intensity?	☐ Yes ☐ No
3 points? Please Note: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score ranges from 0 [clear skin] to 4 [severe disease].	Is the patient currently receiving Spevigo subcutaneous?	☐ Yes ☐ No
or equal to 2 points?  Does the patient have new or worsening pustules?  Does the patient have erythema and pustules which affects greater than or equal to 5% of body surface area?  Yes No  Has patient had increase in GPPGA total score > or = to 2 points  Has the patient already received Spevigo intravenous?  Yes No  Has the patient already received two doses of Spevigo intravenous for treatment of the current flare?  Has the patient already received two doses of Spevigo intravenous for a previous flare?  Yes No  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Yes No  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Yes No	3 points? Please Note: The Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) total score range	s from 0 [clear
Does the patient have erythema and pustules which affects greater than or equal to 5% of body surface area?    Yes   No   No   Has patient had increase in GPPGA total score > or = to 2 points   Yes   No   No     Has the patient already received Spevigo intravenous?   Yes   No   No     Has the patient already received two doses of Spevigo intravenous for treatment of the current flare?   Yes   No   No     Has the patient already received two doses of Spevigo intravenous for a previous flare?   Yes   No     Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No     Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No     Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No     Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No		
Has patient had increase in GPPGA total score > or = to 2 points    Yes   No     Has the patient already received Spevigo intravenous?   Yes   No     Has the patient already received two doses of Spevigo intravenous for treatment of the current flare?   Yes   No     Has the patient already received two doses of Spevigo intravenous for a previous flare?   Yes   No     Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No     Is the request for treatment of a new flare?   Yes   No     Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No     Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No     Have at least 12 weeks have elapsed since the last dose of Spevigo?   Yes   No	Does the patient have new or worsening pustules?	☐ Yes ☐ No
Has the patient already received Spevigo intravenous?  Has the patient already received two doses of Spevigo intravenous for treatment of the current flare?  Has the patient already received two doses of Spevigo intravenous for a previous flare?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Have at least 12 weeks have elapsed since the last dose of Spevigo?	Does the patient have erythema and pustules which affects greater than or equal to 5% of body surface area?	☐ Yes ☐ No
Has the patient already received two doses of Spevigo intravenous for treatment of the current flare?  Has the patient already received two doses of Spevigo intravenous for a previous flare?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Yes No  Is the request for treatment of a new flare?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Yes No	Has patient had increase in GPPGA total score > or = to 2 points	☐ Yes ☐ No
Has the patient already received two doses of Spevigo intravenous for a previous flare?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Is the request for treatment of a new flare?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Yes No  Have at least 12 weeks have elapsed since the last dose of Spevigo?	Has the patient already received Spevigo intravenous?	☐ Yes ☐ No
Is the request for treatment of a new flare?  Have at least 12 weeks have elapsed since the last dose of Spevigo?  Yes No		
Have at least 12 weeks have elapsed since the last dose of Spevigo?	Have at least 12 weeks have elapsed since the last dose of Spevigo?	☐ Yes ☐ No
	Is the request for treatment of a new flare?	☐ Yes ☐ No
Have at least 7 days elapsed since the last dose of Spevigo?	Have at least 12 weeks have elapsed since the last dose of Spevigo?	☐ Yes ☐ No
	Have at least 7 days elapsed since the last dose of Spevigo?	☐ Yes ☐ No
Additional Information Please provide any additional pertinent clinical information, including: if the patient is currently on the requested drug (with dates of use) and how they have been receiving it (for example: samples, out of pocket).		ly on the
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.		
Prescriber Signature: Date:  Save Time! Submit Online at: <a href="https://www.covermymeds.com/main/prior-authorization-forms/cigna/">www.covermymeds.com/main/prior-authorization-forms/cigna/</a> or via SureScripts in your EHR.		pts in your FHR

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.